Evidence map›Paper›PMID 28245430›Full record

ArticleGastroenterology2017

MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.

Zhang-Hui Chen, Yan P Yu, Junyan Tao, Silvia Liu, George Tseng, Michael Nalesnik, Ronald Hamilton, Rohit Bhargava, Joel B Nelson, Arjun Pennathur and 4 more

Abstract read
In one paragraph

Article in Gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. An overview of pyridazin-3(2Future medicinal chemistry · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Fer and FerT: A New Regulatory Link between Sperm and Cancer Cells.International journal of molecular sciences · 2023
    Review
  19. Translational cancer research · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Zhang-Hui ChenDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Yan P YuDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Junyan TaoDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Silvia LiuDepartment of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
George TsengDepartment of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Michael NalesnikDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Ronald HamiltonDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Rohit BhargavaDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Joel B NelsonDepartment of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Arjun PennathurDepartment of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Satdarshan P MongaDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
James D LuketichDepartment of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
George K MichalopoulosDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Jian-Hua LuoDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
University of Pittsburgh · US

Funding

The Role of Myopodin in Invasive Prostate CancersR01CA098249 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LUO, JIANHUA · 2003 to 2014
$2.6M
Use of Quantitative RT-PCR for Staging Esophageal CancerR01CA090665 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LUKETICH, JAMES D · 2001 to 2009
$2.5M
Power calculation and design issues in next-generation sequencingR01CA190766 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TSENG, GEORGE C. · 2015 to 2018
$876k
Genome targeting of liver cancerR56CA229262 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LUO, JIANHUA · 2018 to 2019
$705k
NCI NIH HHS R01 CA090665NCI NIH HHS R01 CA098249NCI NIH HHS R01 CA190766NCI NIH HHS R56 CA229262
6 · The paper itself

Abstract

BACKGROUND &

aimsHuman tumors and liver cancer cell lines express the product of a fusion between the first 13 exons in the mannosidase α class 2A member 1 gene (MAN2A1) and the last 6 exons in the FER tyrosine kinase gene (FER), called MAN2A1-FER. We investigated whether MAN2A1-FER is expressed by human liver tumors and its role in liver carcinogenesis.

methodsWe performed reverse transcription polymerase chain reaction analyses of 102 non-small cell lung tumors, 61 ovarian tumors, 70 liver tumors, 156 glioblastoma multiform samples, 27 esophageal adenocarcinomas, and 269 prostate cancer samples, as well as 10 nontumor liver tissues and 20 nontumor prostate tissues, collected at the University of Pittsburgh. We also measured expression by 15 human cancer cell lines. We expressed a tagged form of MAN2A1-FER in NIH3T3 and HEP3B (liver cancer) cells; Golgi were isolated for analysis. MAN2A1-FER was also overexpressed in PC3 or DU145 (prostate cancer), NIH3T3 (fibroblast), H23 (lung cancer), and A-172 (glioblastoma multiforme) cell lines and knocked out in HUH7 (liver cancer) cells. Cells were analyzed for proliferation and in invasion assays, and/or injected into flanks of severe combined immunodeficient mice; xenograft tumor growth and metastasis were assessed. Mice with hepatic deletion of PTEN were given tail-vein injections of MAN2A1-FER.

resultsWe detected MAN2A1-FER messenger RNA and fusion protein (114 kD) in the hepatocellular carcinoma cell line HUH7, as well as in liver tumors, esophageal adenocarcinoma, glioblastoma multiforme, prostate tumors, non-small cell lung tumors, and ovarian tumors, but not nontumor prostate or liver tissues. MAN2A1-FER protein retained the signal peptide for Golgi localization from MAN2A1 and translocated from the cytoplasm to Golgi in cancer cell lines. MAN2A1-FER had tyrosine kinase activity almost 4-fold higher than that of wild-type FER, and phosphorylated the epidermal growth factor receptor at tyrosine 88 in its N-terminus. Expression of MAN2A1-FER in 4 cell lines led to epidermal growth factor receptor activation of BRAF, MEK, and AKT; HUH7 cells with MAN2A1-FER knockout had significant decreases in phosphorylation of these proteins. Cell lines that expressed MAN2A1-FER had increased proliferation, colony formation, and invasiveness and formed larger (>2-fold) xenograft tumors in mice, with more metastases, than cells not expressing the fusion protein. HUH7 cells with MAN2A1-FER knockout formed smaller xenograft tumors, with fewer metastases, than control HUH7 cells. HUH7, A-172, and PC3 cells that expressed MAN2A1-FER were about 2-fold more sensitive to the FER kinase inhibitor crizotinib and the epidermal growth factor receptor kinase inhibitor canertinib; these drugs slowed growth of xenograft tumors from MAN2A1-FER cells and prevented their metastasis in mice. Hydrodynamic tail-vein injection of MAN2A1-FER resulted in rapid development of liver cancer in mice with hepatic disruption of Pten.

conclusionsMany human tumor types and cancer cell lines express the MAN2A1-FER fusion, which increases proliferation and invasiveness of cancer cell lines and has liver oncogenic activity in mice.

Indexed as

Gene FusionOncogenesalpha-MannosidaseAnimalsAntineoplastic AgentsCell Line, TumorCell MovementCell ProliferationCell Transformation, NeoplasticCrizotinibDose-Response Relationship, DrugEnzyme ActivationErbB ReceptorsGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticGolgi Apparatusalpha-MannosidaseAntineoplastic AgentsCanertinibCrizotinibEGFR protein, humanErbB ReceptorsMAN2A1-FER fusion protein, humanMorpholinesOncogene Proteins, FusionProtein Kinase InhibitorsProtein-Tyrosine KinasesPTEN PhosphohydrolasePten protein, mousePyrazolesPyridinesBiomarkerDriverEctopic ActivationFusion Gene

Identifiers

PMID28245430
PMCPMC5572118
OpenAlexW2594488303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.